Malignant otitis externa and skull base osteomyelitis ICD-10 H60.2 and M86
Differentiating clues
Pattern recognition
Pain with tragal or pinna manipulation favoring otitis externa
Middle ear effusion or bulging tympanic membrane favoring otitis media
Vesicles and facial weakness favoring zoster oticus
Diffuse pinna swelling and sparing of lobule favoring perichondritis
Postauricular swelling and auricle protrusion favoring mastoiditis
Severe night pain and granulation tissue in diabetes favoring malignant otitis externa
Laboratory Tests
Routine labs and when they matter
Baseline testing strategy
No routine labs for uncomplicated acute otitis externa
Point of care glucose for diabetes concern or severe infection
HbA1c coordination in recurrent disease with suspected uncontrolled diabetes
Severe disease and extension evaluation
Invasive infection workup
Complete blood count for systemic infection concern
Leukocytosis as supportive not diagnostic
Normal count does not exclude invasive disease in immunocompromised
C reactive protein for suspected malignant otitis externa
Elevated values supporting inflammatory burden
Trend utility for treatment response
ESR for suspected skull base osteomyelitis
Elevated values common in malignant otitis externa
Trend utility during prolonged therapy
Blood cultures if sepsis physiology
Yield highest when febrile or unstable
Microbiology
Culture strategy
Canal swab culture for recurrent or refractory disease
Prior topical antibiotic failure
Immunocompromised host
Suspicion for fungal infection
Culture limitations
Contamination from colonizing flora
Clinical response remains primary endpoint in uncomplicated disease
Diagnostic Tests
Scoring Systems
Risk stratification framework
Uncomplicated acute otitis externa category
Localized canal inflammation
No fever
No periauricular cellulitis
No cranial neuropathy
No immunocompromised host
Severe acute otitis externa category
Marked canal edema with near occlusion
Severe otalgia limiting sleep or function
Failure of topical therapy at 48 to 72 hours
Periauricular cellulitis
Suspected malignant otitis externa category
Diabetes or immunocompromised host
Severe nocturnal otalgia
Granulation tissue in canal
Cranial nerve deficits
Elevated ESR or CRP if obtained
MRI
Skull base and soft tissue extension
Indications
Suspected malignant otitis externa with cranial neuropathy
Concern for skull base osteomyelitis extent
Concern for intracranial extension
Advantages
Soft tissue delineation
Marrow involvement sensitivity
Limitations
Availability and time
Motion artifact in severe pain
Less detailed bony cortex evaluation than CT
CT
Temporal bone assessment
Indications
Suspected malignant otitis externa
Suspected mastoiditis
Suspected deep extension or abscess
Technique considerations
CT temporal bone with contrast when abscess or soft tissue extension concern
Noncontrast CT temporal bone for bony erosion screening
Interpretation pearls
Bony erosion of external auditory canal suggesting invasive disease
Mastoid opacification with clinical mastoiditis correlation
Evidence note
ACEP Level C recommendation for imaging when invasive complications suspected
Ultrasound
Point of care applications
Periauricular soft tissue ultrasound for cellulitis versus abscess
Fluid collection supporting drainage need
Cobblestoning supporting cellulitis
Lymph node ultrasound for reactive adenopathy context
Limitations
Poor visualization of bony structures
Not a rule out test for malignant otitis externa or mastoiditis
Disposition
Outpatient management
Discharge suitability
Uncomplicated acute otitis externa category features
Pain controlled with oral regimen
Reliable drop administration plan
Follow up access within 3 to 7 days if not improving
Follow up targets
Primary care follow up for routine cases
ENT follow up for recurrent disease
Recheck in 48 to 72 hours if severe canal edema or wick placement
Admission and transfer
Admission indications
Suspected malignant otitis externa
Cranial neuropathy
Sepsis physiology
Immunocompromised with severe disease
Failure of outpatient therapy with worsening extension
Transfer and higher level care triggers
Need for urgent ENT procedural care not available locally
Suspected skull base osteomyelitis requiring prolonged IV therapy
Treatment
Analgesia and symptom control
Pain control plan
Acetaminophen oral
Adult dosing
650 mg every 6 hours as needed
Maximum 3000 mg per 24 hours when no risk factors
Pediatrics dosing
15 mg per kg every 6 hours as needed
Maximum 60 mg per kg per 24 hours
Ibuprofen oral
Adult dosing
400 mg every 6 to 8 hours as needed
Maximum 2400 mg per 24 hours
Pediatrics dosing
10 mg per kg every 6 to 8 hours as needed
Maximum 40 mg per kg per 24 hours
If severe pain despite above, short course opioid strategy
Hydromorphone oral
1 mg every 6 hours as needed
Avoid in opioid naive when possible
Oxycodone oral
5 mg every 6 hours as needed
Avoid with significant respiratory risk
Antiemetic support
Ondansetron oral disintegrating tablet
4 mg every 8 hours as needed
Canal management and drop delivery
Aural toilet principles
Debris removal to improve drop penetration
Irrigation avoidance when tympanic membrane integrity uncertain
Suction under direct visualization when available
Ear wick strategy
Indications
Marked canal edema limiting drop delivery
Technique considerations
Compressed wick placement under visualization
Frequent drop saturation to expand wick
Reassessment
Wick removal or replacement at 24 to 72 hours based on swelling
Topical antimicrobial therapy
First line topical regimens for uncomplicated disease
Fluoroquinolone based drops preferred when tympanic membrane perforation possible
Ofloxacin otic 0.3 percent
Adult dosing
10 drops once daily for 7 days
Pediatrics dosing
5 drops once daily for 7 days
Safety
Non ototoxic profile for perforation concern
Ciprofloxacin with hydrocortisone otic
Adult dosing
3 drops twice daily for 7 days
Pediatrics dosing
3 drops twice daily for 7 days when age appropriate per product labeling
Rationale
Steroid component reducing pain and edema
Aminoglycoside containing drops only when tympanic membrane clearly intact
Neomycin polymyxin B hydrocortisone otic
Adult dosing
3 to 4 drops three to four times daily for 7 to 10 days
Pediatrics dosing
3 drops three to four times daily for 7 to 10 days
Precautions
Avoid if perforation possible due to ototoxicity risk
Contact dermatitis risk
Dosing technique education embedded in plan
Warm drops in hand before instillation
Position with affected ear up for 3 to 5 minutes after drops
Gentle tragal pumping to distribute drops
When to add systemic antibiotics
Systemic therapy indications
Periauricular cellulitis extending beyond canal
Fever with systemic symptoms
Immunocompromised host
Suspected malignant otitis externa
Oral antibiotics for cellulitis with low malignant concern
Cephalexin oral
Adult dosing
500 mg four times daily for 5 to 7 days
Pediatrics dosing
25 mg per kg per day divided every 6 to 8 hours for 5 to 7 days
Coverage note
Streptococci and MSSA coverage
If MRSA risk factors, add or substitute MRSA active agent per local patterns
Doxycycline oral
Adult dosing
100 mg twice daily for 5 to 7 days
Pediatrics precaution
Avoid in children under 8 years
Malignant otitis externa therapy pathway
Initial IV antipseudomonal therapy
Piperacillin tazobactam IV
4.5 g every 6 hours
Renal adjustment required
Cefepime IV
2 g every 8 to 12 hours
Renal adjustment required
Oral step down when appropriate and organism susceptible
Ciprofloxacin oral
750 mg twice daily
Prolonged duration under specialist guidance
Monitoring and endpoints
Pain trajectory as key marker
ESR or CRP trend when obtained
Imaging follow up coordinated by ENT or ID
Evidence note
ACEP Level C recommendation for urgent imaging and specialist management when suspected
Antifungal strategy
Otomycosis management
Canal debridement as cornerstone
Topical acidifying agent option
Acetic acid 2 percent otic
4 to 6 drops four times daily for 7 days
Avoid if tympanic membrane perforation possible
Topical antifungal option
Clotrimazole 1 percent solution
Application frequency per local ENT protocol
Avoid middle ear exposure when perforation possible
Reassessment needs
High recurrence without debris removal
Treatment evidence summary
Guideline aligned statements
Topical antibiotic with or without steroid improves pain and clinical cure in uncomplicated disease
Class I recommendation based on specialty guideline consensus
Ear wick improves delivery when canal edema obstructs drops
ACEP Level C recommendation
Systemic antibiotics reserved for extension or high risk hosts
Class I recommendation based on specialty guideline consensus
Special Populations
Pregnancy
Pregnancy considerations
Topical therapy preference
Fluoroquinolone otic drops as low systemic absorption option
Avoid systemic antibiotics unless clear extension
Analgesia selection
Acetaminophen as first line
NSAID avoidance in later pregnancy per obstetric guidance
Escalation triggers
Fever or cellulitis extension prompting obstetric aware management
Geriatric
Older adult considerations
Diabetes prevalence and malignant otitis externa risk
Lower threshold for imaging and ENT involvement
Medication safety
NSAID renal and GI risk
Opioid fall risk
Hearing aids
Temporary discontinuation during acute treatment when feasible
Pediatrics
Pediatric considerations
Weight based dosing for analgesics
Drop administration barriers
Caregiver instruction emphasis
Recheck at 48 to 72 hours for severe edema or wick
Systemic antibiotic selection
Cellulitis extension pathway aligned to pediatric skin infection guidance
Prevention counseling
Avoid cotton swabs
Dry ear after swimming
Background
Epidemiology
Epidemiology overview
Common outpatient and ED diagnosis in warm and humid seasons
Swimmer associated risk pattern
Higher recurrence with underlying dermatitis or frequent water exposure
Pathophysiology
Mechanistic framework
Canal skin barrier disruption
Moisture maceration
Microtrauma
pH alteration
Local inflammation cycle
Edema causing obstruction
Debris retention promoting bacterial growth
Malignant otitis externa pathway
Invasive infection spreading to cartilage and bone
Skull base osteomyelitis risk in diabetes and immunocompromise
Therapeutic Considerations
Why topical therapy works
High local antibiotic concentration
Limited systemic adverse effects
Steroid component reducing edema and pain
Reasons for treatment failure
Inadequate drop delivery due to occlusion
Nonadherence due to pain or technique
Incorrect diagnosis
Fungal infection
Resistant organism in recurrent cases
Prevention principles
Moisture reduction
Trauma avoidance
Dermatitis control
Patient Discharge Instructions
Copy discharge instructions
Discharge instructions
Diagnosis explanation
Ear canal skin infection or inflammation
Expected improvement within 48 to 72 hours after correct drop use
Medication use
Ear drops exactly as prescribed
Technique
Lay with affected ear up after drops for 3 to 5 minutes
Gentle tragal pumping after drops
Activity and water precautions
Keep ear dry during treatment
No swimming until symptoms resolved
Shower precautions with cotton ball lightly coated in petroleum jelly at entrance of ear
No cotton swabs or objects in ear canal
Pain control
Acetaminophen or ibuprofen as directed unless contraindicated
Follow up plan
Recheck in 48 to 72 hours if severe pain or swelling
Routine follow up in 3 to 7 days if not clearly improving
Return to ED now
Fever or chills
Worsening pain after 48 to 72 hours of drops
Spreading redness of ear or face
New swelling behind ear
Facial weakness
Trouble swallowing or speaking
Severe headache or neck stiffness
Uncontrolled diabetes symptoms or high sugars with illness
Coding and diagnosis labels
ICD-10 acute otitis externa unspecified H60.3
ICD-10 acute swimmer ear right H60.31
ICD-10 acute swimmer ear left H60.32
ICD-10 acute swimmer ear bilateral H60.33
SNOMED CT concept acute otitis externa disorder term for documentation
References
Clinical guidelines and evidence sources
Reference set
American Academy of Otolaryngology Head and Neck Surgery Foundation guideline on acute otitis externa
Infectious Diseases references on malignant otitis externa and skull base osteomyelitis
Emergency medicine reference texts for ED management pathways
Antimicrobial stewardship guidance on topical versus systemic therapy for otitis externa
Evidence grading conventions used
Evidence and recommendation labels
ACEP Level A high certainty evidence
ACEP Level B moderate certainty evidence
ACEP Level C consensus or limited evidence
Class I recommended or indicated
Class IIa reasonable
Class IIb may be considered
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.